Zentalis to Present TNBC ADC Combination and Cyclin E1 Ovarian Cancer Data at AACR
Zentalis will showcase two azenosertib posters at AACR 2026, detailing preclinical azenosertib ADC combinations for TNBC and Cyclin E1 biomarker findings in ovarian cancer. The data support expanding azenosertib into TNBC and targeting Cyclin E1-positive platinum-resistant ovarian cancer, a population lacking approved treatments and comprising ~50% of PROC patients.
1. Poster Presentations at AACR 2026
Zentalis will present two posters on its WEE1 inhibitor azenosertib at the American Association for Cancer Research Annual Meeting, April 17–22, 2026 in San Diego. Abstract #2012 covers preclinical single-agent and combination activity in TNBC models, while Abstract #1708 details real-world Cyclin E1-positive ovarian cancer outcomes.
2. TNBC ADC Combination Data
Preclinical studies demonstrate that combining azenosertib with antibody-drug conjugates and chemotherapy yields enhanced tumor cell kill in triple-negative breast cancer models. Elevated Cyclin E1 expression in TNBC appears to sensitize tumors to WEE1 inhibition, positioning azenosertib ADC combos as a potential new therapeutic strategy.
3. Cyclin E1 Biomarker Findings in Ovarian Cancer
Real-world data confirm that Cyclin E1 protein overexpression correlates with poor prognosis in platinum-resistant ovarian cancer patients. Approximately 50% of PROC cases exhibit Cyclin E1 positivity, underscoring the need for biomarker-driven monotherapy approaches in this unmet patient population.
4. Pipeline Expansion and Clinical Strategy
These AACR presentations support Zentalis’s strategy to broaden azenosertib development beyond ovarian cancer into TNBC and other indications. Positive preclinical and biomarker findings could enhance the company’s late-stage pipeline value and attract partnerships for combination trials.